Abstract
NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.
Original language | English |
---|---|
Pages (from-to) | 13-6 |
Number of pages | 4 |
Journal | Journal of Inherited Metabolic Disease |
Volume | 26 |
Issue number | 1 |
Publication status | Published - 1 Jan 2003 |